UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1470-1
Program Prior Authorization/Notification
Medication Tryngolza™ (olezarsen)
P&T Approval Date 2/2025
Effective Date 5/1/2025
1. Background:
Tryngolza™ (olezarsen) is an APOC-III-directed antisense oligonucleotide (ASO) indicated as
an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome
(FCS).
2. Coverage Criteriaa:
A. Initial Authorization
1. Tryngolza will be approved based on the following criterion:
a. Diagnosis of familial chylomicronemia syndrome (FCS) (i.e., monogenic
chylomicronemia, type 1 hyperlipoproteinemia)
Authorization will be issued for 12 months
B. Reauthorization
1. Tryngolza will be approved based on the following criterion:
a. Documentation of positive clinical response to Tryngolza therapy (e.g., reduction in
triglycerides, reduction in episodes of acute pancreatitis)
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits and medical necessity may be in place.
4. References:
1. Tryngolza [package insert]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; December 2024.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Tryngolza™ (olezarsen)
Change Control
Date Change
2/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
2